Market cap
$2,375 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
5.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 1,330.29 | 1,408.09 | 824.37 | -- | -- |
| EBIT | -38.14 | -55.53 | -11.03 | -198.68 | -264.47 |
| Net Profit | -18.05 | -28.84 | 1.27 | -184.81 | -259.65 |
| EPS | -30.65 | -8.23 | 13.05 | -16.66 | -16.18 |
| Book Value | -- | -- | -- | -- | -6.21 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-22 | Dec-21 | Dec-20 |
| EBIT-Margin
| -4,639.52 | -4,639.52 | -993.88 | -8,285.16 | -- |
| Net Margin
| -12,167.54 | -11,496.91 | -- | -7,425.83 | -16,909.26 |
| Return on equity
| 86.32 | 125.51 | 133.43 | 48.72 | 76.81 |
| Return on Capital
| 93.91 | 130.07 | 155.86 | 48.86 | 77.02 |
| Return on Assets
| -79.84 | -71.96 | -60.98 | -86.64 | -91.91 |
| Debt to Equity (x)
| -- | -- | 0.20 | 0.00 | 0.00 |
Profitability
ROCE
155.86
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
155.86
|
48.86
|
77.02
|
434.96
|
-66.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
133.43
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
133.43
|
48.72
|
76.81
|
434.96
|
-66.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-60.98
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-60.98
|
-86.64
|
-91.91
|
-57.21
|
-63.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-993.88
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-993.88
|
-8,285.16
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-880.69
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-880.69
|
-7,425.83
|
-16,909.26
|
-3,882.06
|
-17,770.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
8.24
--
Year on year growth in net sales
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
8.24
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-10.89
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-10.89
|
-15.94
|
-124.66
|
-66.41
|
-191.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
0.76
--
Year on year growth in profit after tax
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
0.76
|
-16.08
|
-133.62
|
-59.37
|
-189.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.17
--
Year on year growth in earnings per share
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
0.17
|
0.04
|
-0.84
|
0.14
|
-0.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.20
--
Total debt / Net worth
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
0.20
|
0.00
|
0.00
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.93
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
1.93
|
4.44
|
7.56
|
22.39
|
32.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
1.92
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
1.92
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-123.59
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-123.59
|
-791.63
|
-161.83
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.54
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
10.54
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.07
--
Sales / Average Total Assets
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
0.07
|
0.01
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
38.49
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
38.49
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
878.17
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
878.17
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
3,676.40
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
3,676.40
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-2,759.74
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-2,759.74
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-6.98
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-6.98
|
-3.09
|
-8.94
|
-14.48
|
-1.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
6.51
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
6.51
|
-1.21
|
-4.96
|
-7.73
|
0.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-5.23
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
-5.23
|
-2.26
|
-7.62
|
--
|
0.74
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|